Epidermal Growth Factor Receptor Inhibition in Lung Cancer: the Evolving Role of Individualized Therapy

Overview

Journal Cancer Metastasis Rev

Specialty Oncology

Date 2010 Feb 4

PMID 20127143

Citations 40

Authors

Adi F Gazdar

Affiliations

Soon will be listed here.

Abstract

Non-small cell lung cancer (NSCLC) is the major cause of cancer-related deaths in the USA and worldwide. Most patients present with advanced disease, and treatment options for these patients are generally limited to platinum-based chemotherapy and a few targeted therapies. Targeted agents currently in use for NSCLC inhibit oncogenic receptor tyrosine kinase pathways, such as the epidermal growth factor receptor (EGFR) pathway. While current EGFR-targeted agents, including erlotinib and gefitinib, may result in dramatic responses, they demonstrate efficacy in only a fraction of patients, and resistance to these agents frequently develops. In order to select patients most likely to benefit from blockade of EGFR pathways, investigators have focused on identifying molecular correlates of response to anti-EGFR therapy. New strategies to minimize the risk of resistance to EGFR inhibition have been employed in the development of next-generation EGFR tyrosine kinase inhibitors, such as PF00299804 and BIBW 2992; these include irreversibility of target binding, inhibition of multiple EGFR family receptors, and/or simultaneous inhibition of EGFR and other oncogenic pathways.

Citing Articles

Involvement of HDAC2-mediated kcnq2/kcnq3 genes transcription repression activated by EREG/EGFR-ERK-Runx1 signaling in bone cancer pain.

Zhang Z, Tian Y, Li S, Jing H, Cai J, Li M Cell Commun Signal. 2024; 22(1):416.

PMID: 39192337 PMC: 11350972. DOI: 10.1186/s12964-024-01797-2.

Deep Learning-Based H-Score Quantification of Immunohistochemistry-Stained Images.

Wen Z, Luo D, Wang S, Rong R, Evers B, Jia L Mod Pathol. 2023; 37(2):100398.

PMID: 38043788 PMC: 11141889. DOI: 10.1016/j.modpat.2023.100398.

Conversion from Positive to Negative EGFR Mutation due to Clonal Selection during Long-Term Treatment with Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors: A Case Report.

Ueda M, Namba M, Tokumo K, Senoo T, Okamoto W, Yamauchi M Case Rep Oncol. 2021; 14(3):1447-1453.

PMID: 34899235 PMC: 8613632. DOI: 10.1159/000518246.

Evaluation of molecular subtypes and clonal selection during establishment of patient-derived tumor xenografts from gastric adenocarcinoma.

Peille A, Vuaroqueaux V, Wong S, Ting J, Klingner K, Zeitouni B Commun Biol. 2020; 3(1):367.

PMID: 32647357 PMC: 7347869. DOI: 10.1038/s42003-020-1077-z.

Expression of female sex hormone receptors and its relation to clinicopathological characteristics and prognosis of lung adenocarcinoma.

Lee J, Kim H, Shin B J Pathol Transl Med. 2019; 54(1):103-111.

PMID: 31718122 PMC: 6986970. DOI: 10.4132/jptm.2019.10.12.

References

Zhang X, Chang A . Molecular predictors of EGFR-TKI sensitivity in advanced non-small cell lung cancer. Int J Med Sci. 2008; 5(4):209-17. PMC: 2467518. DOI: 10.7150/ijms.5.209. View

Britten C . Targeting ErbB receptor signaling: a pan-ErbB approach to cancer. Mol Cancer Ther. 2004; 3(10):1335-42. View

Aita M, Fasola G, Defferrari C, Brianti A, Dal Bello M, Follador A . Targeting the VEGF pathway: antiangiogenic strategies in the treatment of non-small cell lung cancer. Crit Rev Oncol Hematol. 2008; 68(3):183-96. DOI: 10.1016/j.critrevonc.2008.05.002. View

Alvarez R, Kantarjian H, Cortes J . Biology of platelet-derived growth factor and its involvement in disease. Mayo Clin Proc. 2006; 81(9):1241-57. DOI: 10.4065/81.9.1241. View

Dziadziuszko R, Witta S, Cappuzzo F, Park S, Tanaka K, Danenberg P . Epidermal growth factor receptor messenger RNA expression, gene dosage, and gefitinib sensitivity in non-small cell lung cancer. Clin Cancer Res. 2006; 12(10):3078-84. DOI: 10.1158/1078-0432.CCR-06-0106. View

Kelly K, Chansky K, Gaspar L, Albain K, Jett J, Ung Y . Phase III trial of maintenance gefitinib or placebo after concurrent chemoradiotherapy and docetaxel consolidation in inoperable stage III non-small-cell lung cancer: SWOG S0023. J Clin Oncol. 2008; 26(15):2450-6. DOI: 10.1200/JCO.2007.14.4824. View

Laskin J, Sandler A . Epidermal growth factor receptor: a promising target in solid tumours. Cancer Treat Rev. 2004; 30(1):1-17. DOI: 10.1016/j.ctrv.2003.10.002. View

Mok T, Wu Y, Thongprasert S, Yang C, Chu D, Saijo N . Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med. 2009; 361(10):947-57. DOI: 10.1056/NEJMoa0810699. View

Yoshimura N, Kudoh S, Kimura T, Mitsuoka S, Matsuura K, Hirata K . EKB-569, a new irreversible epidermal growth factor receptor tyrosine kinase inhibitor, with clinical activity in patients with non-small cell lung cancer with acquired resistance to gefitinib. Lung Cancer. 2005; 51(3):363-8. DOI: 10.1016/j.lungcan.2005.10.006. View

10.

Shepherd F, Pereira J, Ciuleanu T, Tan E, Hirsh V, Thongprasert S . Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med. 2005; 353(2):123-32. DOI: 10.1056/NEJMoa050753. View

11.

Friday B, Yu C, Dy G, Smith P, Wang L, Thibodeau S . BRAF V600E disrupts AZD6244-induced abrogation of negative feedback pathways between extracellular signal-regulated kinase and Raf proteins. Cancer Res. 2008; 68(15):6145-53. DOI: 10.1158/0008-5472.CAN-08-1430. View

12.

Mack P, Holland W, Burich R, Sangha R, Solis L, Li Y . EGFR mutations detected in plasma are associated with patient outcomes in erlotinib plus docetaxel-treated non-small cell lung cancer. J Thorac Oncol. 2009; 4(12):1466-72. DOI: 10.1097/JTO.0b013e3181bbf239. View

13.

Burris 3rd H . Shortcomings of current therapies for non-small-cell lung cancer: unmet medical needs. Oncogene. 2009; 28 Suppl 1:S4-13. DOI: 10.1038/onc.2009.196. View

14.

John T, Liu G, Tsao M . Overview of molecular testing in non-small-cell lung cancer: mutational analysis, gene copy number, protein expression and other biomarkers of EGFR for the prediction of response to tyrosine kinase inhibitors. Oncogene. 2009; 28 Suppl 1:S14-23. DOI: 10.1038/onc.2009.197. View

15.

Gridelli C, Maione P, Rossi A . The potential role of mTOR inhibitors in non-small cell lung cancer. Oncologist. 2008; 13(2):139-47. DOI: 10.1634/theoncologist.2007-0171. View

16.

Eberhard D, Giaccone G, Johnson B . Biomarkers of response to epidermal growth factor receptor inhibitors in Non-Small-Cell Lung Cancer Working Group: standardization for use in the clinical trial setting. J Clin Oncol. 2008; 26(6):983-94. DOI: 10.1200/JCO.2007.12.9858. View

17.

Hynes N, Lane H . ERBB receptors and cancer: the complexity of targeted inhibitors. Nat Rev Cancer. 2005; 5(5):341-54. DOI: 10.1038/nrc1609. View

18.

Zhu C, da Cunha Santos G, Ding K, Sakurada A, Cutz J, Liu N . Role of KRAS and EGFR as biomarkers of response to erlotinib in National Cancer Institute of Canada Clinical Trials Group Study BR.21. J Clin Oncol. 2008; 26(26):4268-75. DOI: 10.1200/JCO.2007.14.8924. View

19.

Sandler A, Gray R, Perry M, Brahmer J, Schiller J, Dowlati A . Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med. 2006; 355(24):2542-50. DOI: 10.1056/NEJMoa061884. View

20.

Ladanyi M, Pao W . Lung adenocarcinoma: guiding EGFR-targeted therapy and beyond. Mod Pathol. 2008; 21 Suppl 2:S16-22. DOI: 10.1038/modpathol.3801018. View